GeneDx Holdings
GeneDx Holdings Corp is an American genomic testing and clinical diagnostics company specializing in rare disease testing, exome and genome sequencing, and hereditary cancer screening. The company operates advanced clinical genomics laboratories, providing comprehensive diagnostic testing services, genetic interpretation, and actionable genomic data to physicians, hospitals, and clinical researchers globally. Its core business activities encompass clinical genomic sequencing, rare disease diagnostic testing, bioinformatics analysis, and healthcare data services. Revenue is derived primarily from clinical diagnostic testing service fees, genomic sequencing charges, and healthcare institutional partnerships. GeneDx holds a leading market position in clinical exome and genome sequencing and rare disease diagnostics in the United States. The company is headquartered in Stamford, Connecticut, United States, and its common stock trades on the Nasdaq Global Select Market.
4 of the funds FundTelligence covers report a position in GeneDx Holdings.
- Legal name
- GeneDx Holdings Corp
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 4
- Exposure themes
- Genetic Testing, Molecular Diagnostics, Precision Medicine & Genomics
Funds holding GeneDx Holdings
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.15 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)